Vaccine Manufacture and Supply – News and Features

Here, we explore some of the reasons behind vaccine hesitancy and highlight potential ways to combat the issue.

Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.

Cold-chain distribution requirements complicate vaccine access, reducing vaccination rates for life-threatening, but preventable diseases. Now, researchers have developed a portable production platform for shelf-stable, antibacterial vaccines.

Researchers at Rutgers University have developed a novel approach for delivering DNA therapeutics that relies on suction.

The current standard for women receiving the human papillomavirus (HPV) vaccine is a three-dose regimen, however, a randomized controlled trial of 2,275 women in Kenya has shown that a single dose was highly effective.

A study has analyzed a quarter-century of national survey data to better understand how social, economic and geographical inequalities in India shaped the chances of children remaining unvaccinated between 1992 and 2016.

Speciality vaccine company Valneva has announced topline results from its Phase III trial of the inactivated, adjuvanted COVID-19 vaccine candidate VLA2001.

Bioelectronic assays extend our ability to quickly study interactions between cells, viruses, and therapeutics in real time over days, in one plate, without interference by labels or tags. This article highlights how the effect of various therapeutics on the cell-killing behavior of SARS-CoV-2 was assessed using a bioelectronic assay.

This article explores the concept of vaccine stockpiling, and how genomic surveillance and mathematical modeling can help us to understand its potential impact on the SARS-CoV-2 virus and the pandemic response.

The need for new vaccines for HIV, Tuberculosis (TB) and malaria are all the greater after the pandemic, but will vaccine advances for SARS-CoV-2 help? Anthony King explores for Technology Networks.